
https://www.science.org/content/blog-post/sudden-onset-promiscuity
# Sudden Onset of Promiscuity (November 2012)

## 1. SUMMARY
This 2012 article discusses molecular promiscuity in drug discovery - the phenomenon where structurally similar compounds show dramatically different selectivity profiles against biological targets. The piece analyzes a *Journal of Medicinal Chemistry* paper that examined matched molecular pairs (MMPs) from the Broad Institute's compound collection, where compounds differed by only one chemical group (such as chloro-for-methoxy substitutions).

The key finding was that while most small chemical modifications cause predictable changes in activity, a small subset (829 out of over 30,000 pairs) showed dramatically different activity across ten or more targets, with some differing by as many as 90+ targets. These "promiscuity cliffs" were largely unpredictable - the analysis revealed no specific substructures or transformations that consistently caused sudden promiscuity. Surprisingly, physical properties like molecular weight and logP changes didn't correlate well with these effects either, though highly promiscuous compounds did tend to have high lipophilicity (logP > 6).

## 2. HISTORY
In the decade following this article, molecular promiscuity research evolved significantly:

**Scientific Developments:**
- The recognition of "frequent hitter" or "pan-assay interference compounds" (PAINS) became institutionalized in drug discovery, with screening libraries systematically filtered to remove problematic scaffolds (though the 2012 paper showed promiscuity wasn't framework-centric)
- The concept of "ligand promiscuity" became embedded in computational chemistry workflows, with tools like ChEMBL incorporating promiscuity analysis capabilities
- The original 2010 Broad Institute dataset referenced in the paper became a foundational resource for chemoinformatics research

**Industrial Impact:**
- Pharmaceutical companies integrated promiscuity screening earlier in discovery pipelines to avoid costly late-stage failures
- Academic screening centers began implementing promiscuity filters as standard practice
- This research contributed to the broader "quality by design" movement in medicinal chemistry, shifting focus from purely potency-driven drug design to multi-parameter optimization including selectivity

**Practical Outcomes:**
- No specific FDA-approved drugs directly resulted from this research (therapeutic areas in the Broad dataset weren't specified)
- The work influenced how pharmaceutical companies evaluate and prioritize compound series, particularly in fragment-based drug discovery
- More sophisticated cheminformatics tools emerged for predicting promiscuity, though the paper's central conclusion about unpredictability remains largely true today

## 3. PREDICTIONS
The article didn't explicitly make predictions about future developments, focusing instead on immediate implications for medicinal chemistry practice.

## 4. INTEREST
**Score: 6/10**
This article sits in the 60th-70th percentile. It addresses an important practical problem in drug discovery with solid empirical evidence, and highlights a fundamental limitation in predictive medicinal chemistry that remains relevant today. The research documented what every medicinal chemist suspected but couldn't systematize - the unpredictable nature of small chemical changes.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20121102-sudden-onset-promiscuity.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_